Nantahala Capital Management LLC boosted its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 10.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,130,149 shares of the company's stock after buying an additional 305,300 shares during the quarter. Evolus makes up approximately 1.5% of Nantahala Capital Management LLC's investment portfolio, making the stock its 9th largest position. Nantahala Capital Management LLC owned approximately 4.94% of Evolus worth $34,557,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Barclays PLC lifted its holdings in Evolus by 268.0% during the 3rd quarter. Barclays PLC now owns 93,662 shares of the company's stock worth $1,518,000 after purchasing an additional 68,213 shares during the last quarter. Geode Capital Management LLC grew its position in Evolus by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,210,621 shares of the company's stock worth $19,616,000 after acquiring an additional 11,027 shares during the last quarter. Lord Abbett & CO. LLC grew its position in Evolus by 23.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company's stock worth $16,126,000 after acquiring an additional 188,685 shares during the last quarter. JPMorgan Chase & Co. grew its position in Evolus by 63.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company's stock worth $2,753,000 after acquiring an additional 65,972 shares during the last quarter. Finally, KBC Group NV bought a new stake in Evolus during the 4th quarter worth $49,000. Institutional investors own 90.69% of the company's stock.
Evolus Trading Up 3.5 %
Shares of EOLS stock traded up $0.40 during mid-day trading on Thursday, reaching $11.80. The stock had a trading volume of 653,607 shares, compared to its average volume of 667,321. The stock's 50-day moving average price is $12.02 and its two-hundred day moving average price is $12.80. Evolus, Inc. has a 52-week low of $8.67 and a 52-week high of $17.82. The firm has a market capitalization of $750.33 million, a PE ratio of -12.97 and a beta of 0.97. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.
Wall Street Analyst Weigh In
EOLS has been the topic of several recent research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Evolus in a report on Wednesday, April 9th. BTIG Research assumed coverage on Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 target price on the stock. Barclays upped their target price on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Finally, HC Wainwright reiterated a "buy" rating and issued a $27.00 target price on shares of Evolus in a report on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $23.75.
Check Out Our Latest Stock Analysis on EOLS
Insider Transactions at Evolus
In other Evolus news, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the sale, the director now directly owns 32,183 shares of the company's stock, valued at $418,057.17. The trade was a 28.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider David Moatazedi sold 6,251 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $12.40, for a total value of $77,512.40. Following the transaction, the insider now directly owns 508,619 shares in the company, valued at approximately $6,306,875.60. This represents a 1.21 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 60,575 shares of company stock worth $794,369. Corporate insiders own 6.10% of the company's stock.
Evolus Profile
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
